First Time Loading...

Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 965.5 DKK 0.46% Market Closed
Updated: May 2, 2024

Genmab A/S
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genmab A/S
Revenue Peer Comparison

Comparables:
ZEAL
ASND
B
BAVA
BIOPOR
SANION

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Revenue
kr16.5B
CAGR 3-Years
18%
CAGR 5-Years
40%
CAGR 10-Years
38%
Zealand Pharma A/S
CSE:ZEAL
Revenue
kr342.8m
CAGR 3-Years
21%
CAGR 5-Years
55%
CAGR 10-Years
48%
Ascendis Pharma A/S
NASDAQ:ASND
Revenue
€266.7m
CAGR 3-Years
237%
CAGR 5-Years
91%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Revenue
kr7.1B
CAGR 3-Years
56%
CAGR 5-Years
70%
CAGR 10-Years
19%
Bioporto A/S
CSE:BIOPOR
Revenue
kr31m
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
6%
Saniona AB
STO:SANION
Revenue
kr16.8m
CAGR 3-Years
27%
CAGR 5-Years
-21%
CAGR 10-Years
N/A

See Also

What is Genmab A/S's Revenue?
Revenue
16.5B DKK

Based on the financial report for Dec 31, 2023, Genmab A/S's Revenue amounts to 16.5B DKK.

What is Genmab A/S's Revenue growth rate?
Revenue CAGR 10Y
38%

Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Genmab A/S have been 18% over the past three years , 40% over the past five years , and 38% over the past ten years .